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ABSTRACT
Ribosomal recruitment of cellular mRNAs depends
on binding of eIF4F to the mRNA’s 50-terminal ‘cap’.
The minimal ‘cap0’ consists of N7-methylguanosine
linked to the first nucleotide via a 50-50 triphosphate
(ppp) bridge. Cap0 is further modified by
20-O-methylation of the next two riboses, yielding
‘cap1’ (m7GpppNmN) and ‘cap2’ (m7GpppNmNm).
However, some viral RNAs lack 20-O-methylation,
whereas others contain only ppp- at their 50-end.
Interferon-induced proteins with tetratricopeptide
repeats (IFITs) are highly expressed effectors of
innate immunity that inhibit viral replication by in-
completely understood mechanisms. Here, we
investigated the ability of IFIT family members to
interact with cap1-, cap0- and 50ppp- mRNAs and
inhibit their translation. IFIT1 and IFIT1B showed
very high affinity to cap-proximal regions of cap0-
mRNAs (K1/2,app 9 to 23nM). The 20-O-methylation
abrogated IFIT1/mRNA interaction, whereas IFIT1B
retained the ability to bind cap1-mRNA, albeit with
reduced affinity (K1/2,app 450nM). The 50-terminal
regions of 50ppp-mRNAs were recognized by IFIT5
(K1/2,app 400nM). The activity of individual IFITs in
inhibiting initiation on a specific mRNA was
determined by their ability to interact with its
50-terminal region: IFIT1 and IFIT1B efficiently
outcompeted eIF4F and abrogated initiation on
cap0-mRNAs, whereas inhibition on cap1- and
50ppp- mRNAs by IFIT1B and IFIT5 was weaker
and required higher protein concentrations.
INTRODUCTION
The innate immune system initiates defensive responses to
infecting viruses and bacteria by recognition of ‘pathogen
associated molecular patterns’ (PAMPs) as ‘non-self’ sig-
natures. Recognition is mediated by pattern-recognition
receptors (PRRs) such as Toll-like receptors and RIG-I-
like receptors (1). PAMPs speciﬁc to viral mRNAs include
the double-stranded nature of RNA replicative intermedi-
ates, the absence of modiﬁed nucleosides (such as N6-
methyladenosine) and single-stranded adenosine/uridine
(AU)-rich regions (1). The 50-termini of some viral
mRNAs also differ from those of cellular mRNAs. The
mRNA cap consists of N7-methylguanosine linked to the
ﬁrst nucleotide via a 50-50 ppp bridge: in the minimal RNA
cap structure, named ‘cap0’, methylation is restricted to
the N7 position of the guanine base, but in higher eukary-
otes, additional methylation occurs at the 20-position of
riboses of the next two nucleotides, yielding the 20-O-
methylated ‘cap1’ (m7GpppNmN) and ‘cap2’
(m7GpppNmNm) (Figure 1A). Although many viral
mRNAs are also capped and 20-O-methylated (2), the
genomic and antigenomic RNAs of negative-stranded
RNA viruses such as inﬂuenza virus (family
Orthomyxoviridae) instead have a 50-terminal ppp (3),
whereas the genomic and subgenomic mRNAs of
Sindbis virus (family Togaviridae) are capped but lack
20-O-methylation (4,5). Nucleic acid recognition by
PRRs activates signaling cascades that trigger the expres-
sion of Type 1 interferons (IFN) (6). IFN secretion
spreads the defensive response to neighboring cells by
binding to IFN receptors, which activates the JAK–
STAT signaling pathway, leading to strong transcriptional
induction of >300 genes (7). The IFN-induced
tetratricopeptide repeat (IFIT) genes are among the
*To whom correspondence should be addressed. Tel: +1 718 270 1034; Fax: +1 718 270 2656; Email: tatyana.pestova@downstate.edu
Correspondence may also be addressed to Christopher U.T. Hellen. Tel: +1 718 270 1034; Fax: +1 718 270 2656; Email: christopher.hellen@
downstate.edu
yThese authors contributed equally to the paper as ﬁrst authors.
3228–3245 Nucleic Acids Research, 2014, Vol. 42, No. 5 Published online 25 December 2013
doi:10.1093/nar/gkt1321
 The Author(s) 2013. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial
re-use, please contact journals.permissions@oup.com
RSW
AS fractionation
DEAE
P-11
Mono Q
Hydroxyapatite
188 
98 
62
49 
38 
28 
(40-50%)
(100-250 mM KCl)
(250-400 mM KCl)
(250 mM KCl)
(180 mM Phosphate buffer)
M
W
n
a
tiv
e 
rIF
IT
1B
17 
14
6 
188 
98 
62
49 
38 
28 
17 
14
6 
Mono S
(170 mM KCl)
B
C
D E
J
F
H
G
I
M
W
Full length
+7 nt
C 1 2T A G
C 1 2 3 4T A G
Full length
+6-8 nt
C T A G
C T A G 1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6
1 2 3 4 5 61
1 2 3 4 5 6
rIF
IT
1B
rIF
IT
1
hI
FI
T1
hI
FI
T2
 
hI
FI
T3
 
hI
FI
T5
 
rIF
IT
1B
rIF
IT
1
hI
FI
T1
hI
FI
T2
 
hI
FI
T3
 
hI
FI
T5
 
1 2 3 4 5 6 7 8C T A G
Full length
+7 nt
Full length
+7 nt
Full length
+7 nt
Full length
+7 nt
Full length
+7 nt
1 2
Sncb mRNA:   5’-GAGAGCCUGACCACGGCAGGACACC...
GCN4 mRNA:   5’-GUAUUUUAUUUUAGUUCAGUUUAUU...
ATF4 mRNA:   5’-GAUUUCUGCUUGCUGUCUGCCGGUU...
β-globin(A) mRNA:   5’-ACACUUGCUUUUGACACAACUGUGU...
β-globin(G) mRNA:   5’-GACACUUGCUUUUGACACAACUGUG...
5’-GGACACUUGCUUUUGACACAACUGUGUUUACUUGCAAAG - CCCAA GAAUAAGAGAACAUUUAGACAGA- AUG-.....
G - C 
G - C 
C - G 
U - A
G - C 
C - G 
G - C 
G - C 
G       U 
 C C 
-18.9 kcal/molStem-MVHL-STOP mRNA:
β-globin 5’ UTR heterologous insertion
recombinant
cap0-Stem-MVHL-STOP mRNA
RSW fraction
cap0-β-globin(G) mRNA
++
+
- rI
FI
T1
B
rIF
IT
1
hI
FI
T1
hI
FI
T5
 
hI
FI
T2
 
hI
FI
T3
 
[32P]cap0-β-globin(G) mRNA
+ + + + + ++
-
hI
FI
T5
rIF
IT
1
hI
FI
T1
hI
FI
T2
 
hI
FI
T3
 
rIF
IT
1B
 
5′ppp-β-globin(G) mRNA
- rIF
IT
1B
rIF
IT
1
hI
FI
T1
cap0-β-globin(G) mRNA
cap0-GCN4 mRNA
cap0-ATF4 mRNA
cap0-Sncb mRNA
rIFIT1B
cap0-β-globin(A) mRNA
rIFIT1B
+ +
+
+ +
+
+
+ +
+ +
+
cap0-Stem-MVHL-STOP mRNA
rIFIT1B
m7GpppG (mM)
m7GpppA (mM)
+
+ + + + ++ +
1
1
2.5
2.5
5
5
A O
N+
N
NH2N
HN
CH
3
OH OH
O
O
P
O
O-
O P
O
O-
O P
O
O-
O
O O
O
Base 1
CH
3
O P
O-
O
O O
O
Base 2
CH
3
O P
O-
O
RNA
Triphosphate RNA 5’ end
7-methylguanosine
(cap0)
cap1
cap2
Full length
+6-8 nt
+12-14 nt
+12-14 nt
Full length
+6-8 nt
+12-14 nt
cap1-β-globin(G) mRNA
- rI
FI
T1
B
rIF
IT
1
hI
FI
T1
hI
FI
T5
 
hI
FI
T2
 
hI
FI
T3
 
C T A G 1 2 3 4 5 6 7
Full length
+6-8 nt
Figure 1. Speciﬁc interaction of IFIT1 and IFIT1B with the 50-terminal regions of cap0 mRNAs. (A) Cap-structure. (B) Structure of the 50UTR of
Stem-MVHL-STOP mRNA (41) and sequences of the 50-terminal 25 nt of b-globin(G), GCN4, ATF4, Sncb and b-globin(A) mRNAs. (C) Interaction
of the active RRL RSW fraction with cap0-Stem-MVHL-STOP mRNA assayed by primer extension. The toe-print induced by the interaction is
indicated. (D) Left panel: scheme for puriﬁcation of IFIT1B from RRL. Right panel: puriﬁed native rIFIT1B resolved by SDS–PAGE. (E) Puriﬁed
recombinant hIFIT1, hIFIT2, hIFIT3, hIFIT5, rIFIT1 and rIFIT1B resolved by SDS–PAGE. (F and G) Interaction of hIFIT1, hIFIT2, hIFIT3,
Nucleic Acids Research, 2014, Vol. 42, No. 5 3229
(continued)
most strongly induced by IFN treatment (e.g. 8,9), for
example leading to the cytoplasmic accumulation of
>1 106 IFIT1 molecules per cell (10). Their abundance
would be consistent with IFIT proteins having an execu-
tive function rather than a signaling role in innate
immunity.
The IFIT family arose by gene duplication and is
conserved in vertebrates (11–13). Most mammals encode
IFIT1, IFIT2, IFIT3 and IFIT5, with the exception of
mice and rats (which lack IFIT5) and horses (which lack
IFIT1), but many species also have additional IFIT-like
genes, encoding IFIT1B (in humans, mice and rabbits),
IFIT1C (in mice), IFIT3B (in dogs and mice) and
IFIT5-like proteins (in dogs and rabbits). IFIT proteins
have molecular weights ranging between 47 and 72 kDa,
and contain up to 11 tetratricopeptide repeat (TPR)
motifs (14) that form a series of tandem antiparallel
a-helices extending over their entire length. The regular
repeating relationship between TPRs is disrupted by two
insertions in IFIT2 and IFIT5, so that the TPRs form
three distinct subdomains producing a V-shaped clamp-
like structure (15–18). The concave surface of subdomain
II, the ‘pivot’ helices between subdomains II and III and
the N-terminal TPRs of subdomain III form a deep cylin-
drical cavity that is lined with positively charged residues
(16–18). Whereas IFIT5 is a monomer, IFIT2 forms a
domain-swapped homodimer in a manner that may
account for conformational switching of subdomains
during binding of ligands (15) and for homo- and
heterodimerization of human IFITs 1, 1B, 2 and 3
(10,18). The functional importance of homo- and
heterodimerization of IFITs is unknown.
The promoters of most IFIT genes contain one to
four IFN-stimulated response elements (ISRE), typically
located within 200 bp upstream of the transcription start
site, that are recognized by IFN regulatory factors, leading
to rapid induction of transcription. A few IFIT genes,
including human IFIT1B, lack ISRE-containing pro-
moters and are not transcriptionally induced by IFN or
dsRNA (11,12). Sequence similarity between the different
IFIT proteins within a species is high (44–98% identity)
(11), but they are differentially expressed depending on the
cell and tissue type, respond differently to IFN and differ-
ent viruses, and have different effects on replication of
individual viruses, suggesting that different IFITs have
non-redundant functions in the host response to viral in-
fection (e.g. 19–23).
Different IFIT members have been reported to inhibit
viral replication through various mechanisms. Thus,
IFIT3 and IFIT5 potentiate antiviral signaling (24,25),
whereas some reports indicate that IFIT1 exhibits the
opposite modulatory effect (26). IFIT2, on the other
hand, has been shown to promote apoptosis via a
mitochondrial pathway (27,28). However, the principal
antiviral function of IFITs is thought to involve inhibition
of viral translation. Over-expression of human IFIT1 in
HT1080 cells reduced overall translation by 40%, and
addition of recombinant human IFIT1 and IFIT2
abrogated cap-dependent translation in rabbit reticulocyte
lysate (RRL) (29). Originally, their mechanism of action
was reported to involve interaction with and impairment
of the functions of eukaryotic initiation factor eIF3
(30,31), a large multisubunit factor that binds to the ribo-
somal 40S subunit and promotes recruitment of mRNA
and the eIF2GTP/initiator tRNA (Met-tRNAiMet)
ternary complex (32,33). However, subsequent studies
were unable to conﬁrm the repression of translation in
RRL by 35 mM IFIT2 (10) or the interaction of IFIT2
with eIF3 (15).
More recent reports have focused on the interactions of
IFITs with RNA, which could impair translation more
directly, by sequestering tRNA or viral mRNA, or
abrogate replication by binding to genomic/antigenomic
RNAs. Determination of the crystal structure of IFIT2
showed that it has a positively charged RNA-binding
channel on the inner surface of its carboxy-terminal
subdomain that binds AU-rich RNAs (15), whereas
IFIT5 has a deep positively charged RNA-binding
pocket that can accommodate single-stranded nucleic
acid with a 50-terminal ppp. The crystal structures of
IFIT5 bound to short 50ppp-RNA oligoribonucleotides
revealed that the 50-terminal phosphate and four
adjacent nucleotides bind to conserved residues in this
cavity in a sequence-independent manner, inducing
closure of the cavity (16). Non-speciﬁc binding of IFIT5
to a variety of short cellular RNAs, including initiator
tRNA, has also been reported (17,34). Positively charged
amino acid residues that inﬂuence binding of initiator
tRNA map to a broad surface, including elements of
domain II and the ‘pivot’ helices between it and domain
III (17).
Human IFIT1 was previously reported to speciﬁcally
bind 50ppp-ssRNAs with moderate afﬁnity
(Kd 250 nM) (10). Two independent groups have
recently reported speciﬁc interaction of human IFIT1
with cap0-RNAs (35,36). These latter reports support
our current ﬁnding, using a novel equilibrium-based
binding assay, that human IFIT1, rabbit IFIT1 and
rabbit IFIT1B speciﬁcally bind to cap-proximal regions
of cap0-mRNAs with very high afﬁnity (K1/2,app 9 to
23 nM). This enables them to compete efﬁciently with
eIF4F and thus to inhibit translation initiation on cap0-
mRNAs through sequestration. Molecular modeling and
mutagenesis of human IFIT1 suggest that the ppp moiety
of cap0 interacts with an extended cleft leading to a pocket
that binds the N7-methylguanosine portion of the cap
Figure 1. Continued
hIFIT5, rIFIT1 and rIFIT1B (400 nM) with cap0-, cap1- and 50ppp- b-globin(G) mRNAs assayed by primer extension. Toe-prints induced by the
IFIT/mRNA interaction are indicated. For better resolution of toe-prints, primer extension in panel (G) was performed using a primer that is closer
to the 50-end of mRNA. (H) UV cross-linking of hIFIT1, hIFIT2, hIFIT3, hIFIT5, rIFIT1 and rIFIT1B with [32P]cap-labeled cap0-b-globin(G)
mRNA. (I) Interaction of rIFIT1B (300 nM) with cap0- GCN4, ATF4, Sncb and b-globin(A) mRNAs. Toe-prints caused by the rIFIT1B/mRNA
interaction are indicated. (J) Competition between rIFIT1B (150 nM) and m7GpppG or m7GpppA dinucleotides for binding to cap0-Stem-MVHL-
STOP mRNA (20 nM). The toe-print induced by the rIFIT1B/mRNA interaction is indicated.
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structure. Whereas the speciﬁc and stable interaction of
IFIT1 with cap0-mRNA may account for its ability to
inhibit translation and thus impair replication of speciﬁc
viruses, the observation that IFIT1B, which lacks an
ISRE-containing promoter and is not transcriptionally
induced by IFN or dsRNA, also binds cap0-mRNAs
suggests that it might regulate translation of speciﬁc
cellular mRNAs in circumstances that are unrelated to
the innate immune response.
MATERIALS AND METHODS
Plasmids
Expression vectors for eIF1 and eIF1A (37), eIF4A and
eIF4B (38), eIF4E (39), hIFIT1 (17), hIFIT2 (10), hIFIT3
(10), hIFIT5 (17) and Escherichia coli methionyl tRNA
synthetase (40), as well as transcription vectors for Stem-
MVHL-STOP mRNA (41), tRNAi
Met (42), tRNALeu and
tRNAHis (43) have been described. A transcription vector
for tRNALys was made by inserting its DNA sequence
ﬂanked by a T7 promoter and a FokI restriction site
into pUC57 (GenScript). The transcription vectors for
b-globin, ATF4, GCN4 and Sncb mRNAs were made
by inserting DNA sequences (corresponding to their
50-terminal 235, 442, 600 and 247 nt, respectively)
ﬂanked by a T7 promoter and HindIII, EcoRV, EcoRV
and HindIII restriction sites, respectively, into pUC57
(GenScript). pET-28a(rIFIT1) for expression of rIFIT1
(NCBI Reference sequence XP_002718421.1) and
pET16b(rIFT1B) for expression of rIFIT1B (NCBI
Reference sequence XP_002718420.1) were made by
Biomatik Inc. (Cambridge, ON, Canada) by inserting syn-
thetic DNA sequences between Nhe1 and BamH1 sites of
pET28a(+) and Nde1 and BamH1 sites of pET16b
(Novagen), respectively. pET16b(hIFIT1B) for expression
of hIFIT1B was made by inserting a DNA fragment
ampliﬁed by polymerase chain reaction from plasmid
HsCD00342660/MGC: 168989 (Genbank Acc. No.
BC137368) from the DF/HCC DNA Resource Core
(Harvard Medical School) between Nde1 and BamH1
sites of pET16b. hIFIT1 mutants were generated by
NorClone Biotech Laboratories (London, ON, Canada)
using a wt IFIT1 expression vector (17). mRNAs and
tRNAs were in vitro transcribed using T7 polymerase.
For EMSA, tRNAi
Met and RNA comprising 62
50-terminal nucleotides of cap0-b-globin(G) mRNA were
transcribed in the presence of [a32P]ATP, [a32P]GTP and
[a32P]CTP (6000Ci/mmol).
Puriﬁcation of initiation factors, 40S ribosomal subunits
and aminoacylation of tRNAi
Met
Native 40S ribosomal subunits, eIF2, eIF3 and eIF4F,
and recombinant eIF1, eIF1A, eIF4A, eIF4B, eIF4E
and E. coli methionyl tRNA synthetase were puriﬁed as
described in (40,44,45). In vitro transcribed tRNAi
Met was
aminoacylated using E. coli methionyl tRNA synthetase
(45). For experiments on 43S complex formation,
aminoacylation was done in the presence of [35S]Met.
Puriﬁcation of native rIFIT1B
Native rIFIT1B was puriﬁed from RRL on the basis of its
activity in binding to cap0-Stem-MVHL-STOP mRNA,
which was monitored by primer extension. The 40–50%
ammonium sulfate precipitation fraction of the 0.5M KCl
ribosomal salt wash that was prepared from 1 l of RRL
(Green Hectares, Oregon, WI, USA) (43) was dialyzed
against buffer A (20mM Tris–HCl, pH 7.5, 10%
glycerol, 2mM DTT, 0.1mM EDTA)+100mM KCl
and applied to a DE52 column equilibrated with buffer
A+100mM KCl. rIFIT1B was eluted by buffer
A+250mM KCl. This fraction was applied to a P11
column equilibrated with buffer A+100mM KCl, and
rIFIT1B was eluted between 250 and 400mM KCl. This
fraction was applied to a FPLC MonoQ HR 5/5 column.
Fractions were collected across a 100–500mM KCl
gradient. rIFIT1B was eluted at 250mM KCl.
rIFIT1B-containing fractions were applied to a hydroxy-
apatite column. Fractions were collected across a
20–500mM phosphate buffer gradient. rIFIT1B was
eluted at 180mM phosphate buffer. rIFIT1B-containing
fractions were applied to a FPLC MonoS HR 5/5 column.
Fractions were collected across a 50–500mM KCl
gradient. rIFIT1B was eluted at 170mM KCl.
rIFIT1B-containing fractions were concentrated on
Microcon YM30 (Millipore).
Puriﬁcation of recombinant IFITs
Recombinant wild-type hIFIT1, hIFIT2, hIFIT3, hIFIT5,
rIFIT1 and rIFIT1B, and hIFIT1 mutants were expressed
in 1 l of BL21 DE3 Star Escherichia coli (Invitrogen). Cells
were grown at 37C to an OD600 of 0.6. Protein produc-
tion was induced by the addition of 0.2mM IPTG, after
which incubation continued for 16 h at 16C. Proteins
were isolated by afﬁnity chromatography on Ni-NTA-
agarose followed by FPLC on a MonoQ HR5/5 column.
After that, rIFIT1B was additionally puriﬁed by FPLC on
a Superdex 200 column.
Capping of mRNA
mRNA (30mg) was included in a capping reaction per-
formed using the T7 mScript Standard mRNA
Production System (Cellscript, Madison, WI, USA).
Cap0- or cap1- mRNAs were generated by omission or
inclusion of 20-O-methyltransferase in the capping
reaction, respectively. N7-unmethylated cap0-mRNA
was generated by performing the capping reaction in the
absence of S-adenosyl-methionine. For UV cross-linking
experiments, capping was performed in the presence of
[a32P]GTP.
Analysis of the IFIT/mRNA interaction by primer
extension inhibition
Cap0-, cap1- and 50ppp- b-globin(G) mRNAs (0.5 nM)
were incubated with IFIT proteins (at concentrations
indicated in Figures and Figure Legends) for 10min at
37C in 100 ml reaction mixtures containing buffer B
(20mM Tris, pH 7.5, 100mM KCl, 2.5mM MgCl2,
1mM ATP, 0.2mM GTP, 1mM DTT and 0.25mM
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spermidine). In competition experiments, reaction
mixtures were also supplemented with m7GpppG,
m7GpppA, eIF4E, eIF4F or tRNAs at concentrations
indicated in Figures and Figure Legends. mRNA/IFIT
association was analyzed by primer extension inhibition,
using avian myeloblastosis virus reverse transcriptase
(AMV-RT) (2.5U) and 32P-labeled primer in the
presence of 4mM MgCl2 and 0.5mM dNTPs. cDNA
products were resolved in a 6% acrylamide sequencing
gel and visualized by autoradiography. The intensities of
full-length and IFIT induced stops were quantiﬁed using
an Amersham Storm 860 Phosphoimager.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was per-
formed essentially as described (46). IFIT proteins (at
concentrations indicated in Figures and Figure Legends)
were incubated with 32P-labeled tRNAi
Met or cap0-RNA
comprising 62 50-terminal nucleotides of cap0-b-globin(G)
mRNA (0.5 nM) at 37C for 10min in 10 ml reaction
mixtures containing buffer B. After addition of 2 ml of
loading buffer (60% glycerol, 0.01% Bromophenol
Blue), samples were applied to non-denaturing 6% acryl-
amide gels and subjected to electrophoresis using 90mM
Tris, 90mM boric acid and 1mM EDTA running buffer.
Bound and unbound fractions were visualized by
autoradiography.
UV cross-linking
[32P]cap-labeled cap0-b-globin(G) mRNA (50 nM) was
incubated with IFIT proteins (200 nM) for 10min at
37C in 20 ml reaction mixtures containing buffer B and
subjected to irradiation on ice for 20min at 254 nm using a
UV Stratalinker (Stratagene). Samples were treated with
RNAses A, V1 and T1 before separation on NuPAGE
4-12% Bis-Tris Gel (Invitrogen). Cross-linked proteins
were visualized by autoradiography.
Analysis of 48S initiation complex formation
48S complexes were assembled by incubation of cap0-
b-globin(G), cap1-b-globin(G) or 50ppp-b-globin(G)
mRNAs (12.5 nM) with 40 S subunits (110 nM), eIF2
(250 nM), eIF3 (150 nM), eIF1 (300 nM), eIF1A
(300 nM), eIF4A (400 nM), eIF4B (150 nM), eIF4F
(150 nM) and Met-tRNAi
Met (200 nM) in the presence or
in the absence of IFITs (at concentrations indicated in
Figures and Figure Legends) for 10min at 37C in 20 ml
reaction mixtures containing buffer B. 48S complex for-
mation was analyzed by toe-printing (43) using AMV-RT
(2.5U) and 32P-labeled primer at 12mM MgCl2 to stabil-
ize 48S complexes. cDNA products were resolved in a 6%
acrylamide sequencing gel and visualized by autoradiog-
raphy. The intensities of full length and IFIT induced
stops were quantiﬁed using an Amersham Storm 860
Phosphoimager.
Ribosomal association of IFITs
IFIT proteins (300 nM) were incubated with 40S riboso-
mal subunits (160 nM) for 15minutes at 37C in 200 ml
reaction mixtures containing buffer B. The reaction
mixtures were then subjected to centrifugation through
10–30% sucrose density gradients in a Beckman SW55
rotor at 53 000 rpm for 90min. Fractions that corres-
ponded to ribosomal complexes were trichloroacetic acid
precipitated and analyzed by sodium dodecyl sulphate–
polyacrylamide gel electrophoresis SDS–PAGE using the
NuPAGE 4–12% Bis-Tris Gel System (Invitrogen) with
subsequent ﬂuorescent SYPRO (Invitrogen) staining.
Analysis of 43S preinitiation complex formation
43S complexes were assembled from 40S ribosomal
subunits (80 nM), eIF2 (120 nM), eIF3 (200 nM), eIF1
(500 nM), eIF1A (500 nM) and [35S]Met-tRNAi
Met
(100 nM; 350 000 cpm) in the presence or in the absence
of hIFIT1 or rIFIT1B (300 nM) in 200 ml reaction
mixtures containing buffer B. Before addition of other
components, IFITs were preincubated with either 40S
subunits, [35S]Met-tRNAi
Met, or [35S]Met-tRNAi
Met and
eIF2 for 10min at 37C. After assembly of ﬁnal
mixtures, incubation continued for an additional 10min.
Assembled complexes were separated by centrifugation
through 10–30% SDGs as described above. 43S complex
formation was analyzed by scintillation counting of an
aliquot of each fraction.
Native gel electrophoresis
The oligomerization status of different IFIT proteins was
analyzed using the NativePAGE Gel system (Invitrogen)
as per the manufacturer’s instructions. A total of 500 ng of
recombinant hIFIT1, hIFIT2, hIFIT3, hIFIT 5, rIFIT1
and rIFIT1B were separated on a 4–16% non-denaturing
Bis-Tris gradient gel (Invitrogen). The gel was run in
50mM Bis-Tris and 50mM Tricine at pH 8. Coomassie
G-250 (0.02%) (Invitrogen) was included as a charge shift
molecule in the cathode buffer. After electrophoresis,
protein bands were visualized using the Novex colloidal
blue staining kit (Invitrogen).
RESULTS
IFIT1 and IFIT1B, but not IFIT2, IFIT3 and IFIT5,
interact speciﬁcally with the 50-terminal regions of
cap0 mRNAs
Routine activity testing during puriﬁcation of the eukary-
otic ribosome recycling factor ABCE1 (47) from RRL,
which involved toe-printing of ribosomal complexes
formed on cap0-Stem-MVHL-STOP mRNA (a derivative
of b-globin mRNA, containing two 50-terminal guanine
nucleotides and a stable stem in the middle of the
50UTR; Figure 1B; 41), revealed that some fractions
induced strong arrest of reverse transcriptase (RT) seven
nucleotides downstream of the 50-end of the mRNA
(Figure 1C), indicating a stable and speciﬁc interaction
between constituents of these fractions and the
50-terminal region of cap0 mRNA. Extensive puriﬁcation
of the active component (Figure 1D, left panel) yielded an
apparently homogenous 55 kDa protein (Figure 1D,
right panel), which was identiﬁed as IFIT1B
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(Supplementary Table S1). To determine whether this
mRNA-binding activity was speciﬁc for rabbit IFIT1B,
the following members of the IFIT family were expressed
and puriﬁed in recombinant form: human (h) IFIT1,
IFIT2, IFIT3 and IFIT5, and rabbit (r) IFIT1 and
IFIT1B (Figure 1E). Attempts to express recombinant
hIFIT1B did not yield a soluble protein. To investigate
the inﬂuence of the nature of mRNA nucleotides on
IFIT/mRNA binding, ﬁve mRNAs with different
50-terminal sequences were employed: b-globin(G) and
b-globin(A) mRNAs with a 50-terminal guanosine or ad-
enosine, respectively, GCN4 mRNA, ATF4 mRNA and
Sncb (beta-synuclein) mRNA (Figure 1B).
At 400 nM, hIFIT1, rIFIT1 and rIFIT1B (but not
hIFIT2, hIFIT3 or hIFIT5) induced +7nt toe-prints on
cap0-b-globin(G) mRNA (Figure 1F, top panel).
Although the +7nt stop was the most prominent in all
cases, the intensity of additional stops at ﬂanking +6
and +8 positions differed: the strongest stop at +8nt
was induced by rIFIT1, whereas the+6nt stop was most
obvious in the case of hIFIT1 (Figure 1G). This subtle
difference suggests that the strength of the mRNA/IFIT
interaction at the 30-border of the interacting mRNA
region varies between the three IFITs. In the case of
rIFIT1B, additional low-intensity toe-prints were also
observed at +1214 positions. Binding of hIFIT1 and
rIFIT1 was speciﬁc for cap0-b-globin(G) mRNA: no RT
arrest was observed on cap1-b-globin(G) mRNA in their
presence (Figure 1F, middle panel). rIFIT1B, on the other
hand, was able to induce a +7nt toe-print on cap1-b-
globin(G) mRNA, but with only half the efﬁciency of
that observed on cap0-b-globin(G) mRNA (Figure 1F,
compare middle and top panels). On b-globin(G)
mRNA containing a 50-terminal ppp, a prominent toe-
print at the +7 position was observed in the presence of
hIFIT5, whereas hIFIT1, rIFIT1 and rIFIT1B induced
only trace-level stops at this position (Figure 1F, bottom
panel). Interestingly, toe-prints induced by hIFIT1 on
cap0-b-globin(G) mRNA, and to a greater extent toe-
prints induced by rIFIT1B and hIFIT5 on cap1- and on
50ppp- b-globin(G) mRNAs, respectively, were sensitive to
elevation of [Mg2+] above 6mM during the primer exten-
sion stage, which most likely indicates that at these
[Mg2+], RT displaces these IFITs from mRNA (PK,
TRS and TVP, unpublished data). No speciﬁc toe-prints
were observed in the presence of hIFIT2 and hIFIT3, ir-
respective of the structure present at the 50-end of mRNA
(Figure 1F, all panels). Consistently, hIFIT1, rIFIT1 and
rIFIT1B, but not hIFIT2, hIFIT3 and hIFIT5 cross-
linked to [32P]cap-labeled cap0-b-globin(G) mRNA
(Figure 1H). Despite sequence differences in the
50-terminal region of the various tested cap0 mRNAs
(Figure 1B), hIFIT1, rIFIT1 and rIFIT1B speciﬁcally
interacted with them all (shown for rIFIT1B in
Figure 1I). Interestingly, the m7GpppG and m7GpppA
dinucleotides were only weak competitors of IFIT/cap0-
mRNA binding (with m7GpppG being slightly stronger
than m7GpppA) (shown for rIFIT1B in Figure 1J), sug-
gesting that the IFIT/cap0-mRNA interaction extends
over several cap-proximal nucleotides.
The afﬁnities of hIFIT1, rIFIT1 and rIFIT1B for
cap0 mRNAs
To determine the afﬁnity of hIFIT1, rIFIT1 and rIFIT1B
for cap0-b-globin(G) mRNA, of rIFIT1B for cap1-b-
globin(G) mRNA, and of hIFIT5 for 50ppp-b-globin(G)
mRNA, the primer extension technique was employed
(Figure 2A–E). Importantly, primer extension is per-
formed under conditions of binding equilibrium, which
represents a signiﬁcant advantage of this method over
non-equilibrium techniques such as the EMSA.
Moreover, in the primer extension assay, unbound and
IFIT-associated mRNAs yield sharp, distinct signals that
could be quantiﬁed with high conﬁdence. In all cases, sig-
moidal binding curves were obtained. All tested IFITs
bound to cap0-b-globin(G) mRNA very tightly
(Figure 2A–C), with similar afﬁnities: K1/2,app=23±
4nM for hIFIT1, K1/2,app=20±1nM for rIFIT1 and
K1/2,app=9±2nM for rIFIT1B. The values of Hill coef-
ﬁcients n> 1 (n=1.6±0.1 for hIFIT1, n=1.7±0.2 for
rIFIT1, and n=1.8±0.2 for rIFIT1B) suggested some
positive cooperativity in each instance. The afﬁnities of
rIFIT1B for cap1-b-globin(G) mRNA (Figure 2D;
K1/2,app=457±24nM) and of hIFIT5 for 5
0ppp-b-
globin(G) mRNA (Figure 2E; K1/2,app=372±21nM)
were similar, but were more than one order of magnitude
lower than those of hIFIT1, rIFIT1 and rIFIT1B for
cap0-b-globin(G) mRNA. No measurable stable binding
to 50ppp-b-globin(G) mRNA was observed for hIFIT1
and rIFIT1 at concentrations of up to 1.4 mM
(Supplementary Figure S1).
Since primer extension only detects speciﬁc binding of
IFITs to the cap-proximal region of mRNA and as it is
highly unlikely that one IFIT molecule contains more than
one such binding site, low-level positive cooperativity
could potentially result only from oligomerization of
IFITs at higher concentrations, if it increases the afﬁnity
of IFITs to cap0-mRNA. In native gel electrophoresis
(Supplementary Figure S2), the highest degree of oligo-
merization was observed for rIFIT1B. hIFIT2 migrated
as a dimer consistent with a previous report (15).
hIFIT3 also showed a high tendency to dimerization,
whereas dimerization of hIFIT1 was lower, and hIFIT5
and rIFIT1 were mostly monomeric.
Consistent with primer extension experiments
(Figure 1F), EMSA also detected binding of cap0-RNA
(comprising 62 50-terminal nucleotides of cap0-b-
globin(G) mRNA; Figure 2F, upper panel) only to
hIFIT1, rIFIT1 and rIFIT1B (Figure 2F, four left
panels), conﬁrming that the lack of binding of hIFIT2,
hIFIT3 and hIFIT5 to cap0 mRNA in primer extension
experiments was not caused by displacement of IFITs by
RT. The mobility of different IFIT/cap0-RNA complexes
was consistent with the tendency of the particular IFIT to
oligomerize (Supplementary Figure S2). Thus, increasing
hIFIT1 concentrations resulted in the progressive appear-
ance of a slower migrating complex, likely corresponding
to hIFIT1 dimers (Figure 2F, ﬁrst panel from the left),
whereas no dimers were observed in the case of rIFIT1
(Figure 2F, second panel from the left). rIFIT1B, on the
other hand, did not form monomeric complexes, and even
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Figure 2. Binding constants for hIFIT1, rIFIT1 and rIFIT1B association with cap0 mRNAs. (A–C) Left panels: representative gels of titration of the
association of hIFIT1, rIFIT1 and rIFIT1B with cap0-b-globin(G) mRNA assayed by primer extension. Toe-prints induced by the IFIT/mRNA
interaction are indicated. Right panels: corresponding plots of the dependence of the fraction of IFIT-bound mRNA on the concentration of IFITs.
The curves were ﬁtted to the non-linear Hill equation (Frac[bound]= [IFIT]n  Frac[bound]max /([IFIT]n+Kn1/2,app)) using GraphPad Prism software.
Dissociation constant (K1/2,app) and Hill coefﬁcient (n) calculated on the basis of at least three independent experiments are shown in the inset boxes.
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(continued)
at the lowest concentrations migrated as a dimer, with the
recombinant form having a stronger tendency to oligo-
merize at higher concentrations and to form high molecu-
lar weight complexes that migrated close to the start
(Figure 2F, third and fourth panels from the left).
Again, as in primer extension experiments (Figure 1F),
no binding to cap1-RNA was observed for hIFIT1,
rIFIT1, hIFIT2, hIFIT3 and hIFIT5, and only a small
amount of complexes formed in the case of rIFITB at
the highest concentration of the protein (Figure 2G). In
control experiments, eIF4E bound to both cap0- and
cap1- RNAs (Figure 2H).
Sensitivity of hIFIT1, rIFIT1 and rIFIT1B to N7-
methylation of the cap, and their competition with eIF4E
and eIF4F for binding to cap0-mRNAs
Next, we investigated the requirement for N7-methylation
of the cap for binding of hIFIT1, rIFIT1 and rIFIT1B to
cap0-b-globin(G) mRNA. Although N7-methylation was
not essential for binding by any of the IFITs (Figure 3A–
C), differences between them were nevertheless observed.
Thus, at lower concentrations, binding of hIFIT1 to
unmethylated cap0-globin(G) mRNA appeared to be
more efﬁcient, but in contrast to binding to methylated
mRNA, did not reach saturation at higher concentrations
(Figure 3A), likely due to a greater degree of displacement
of IFIT by RT, which prevented accurate determination
of the binding constant. In contrast, binding of rIFIT1 to
unmethylated cap0-globin(G) mRNA was weaker
(K1/2,app=81±5nM) than to the methylated equivalent
(Figure 3B). The highest dependence on N7-methylation
was observed for rIFIT1B, which bound to unmethylated
cap0-globin(G) mRNA with the lowest K1/2,app of
340±15nM (Figure 3C).
In competition experiments, association of hIFIT1 and
rIFIT1B with N7-methylated cap0-b-globin(G) mRNA
was not affected by 5- or even 10-fold excess of eIF4E
(Figure 3D) or eIF4F (Figure 3E), irrespective of the
presence of ATP or ADPNP in the reaction mixture.
The effect of hIFIT1, hIFIT2, hIFIT3, hIFIT5, rIFIT1
and rIFIT1B on 48S initiation complex formation on
cap0-, cap1- and 50ppp- mRNAs
The inﬂuence of IFITs on translation initiation was
investigated using an in vitro reconstituted translation
system. 48S complexes were assembled from individual
puriﬁed 40S subunits, Met-tRNAi
Met, eIF2, eIF3, eIF1,
eIF1A, eIF4A, eIF4B and eIF4F on cap0-, cap1- and
50ppp- b-globin(G) mRNAs in the presence and absence
of IFITs, and analyzed by toe-printing. Although IFIT/
mRNA complexes (particularly rIFIT1B/cap1-mRNA
and hIFIT5/50ppp-mRNA complexes) were sensitive to
dissociation by RT at high Mg2+ concentrations, the
toe-printing stage in these experiments was nevertheless
performed at an elevated Mg2+ concentration in order to
‘freeze’ 48S complexes after their assembly. As a result,
toe-prints corresponding to rIFIT1B/cap1-mRNA and
hIFIT5/50ppp-mRNA binary complexes were not
apparent in these experiments. At 800 nM, hIFIT1,
rIFIT1 and rIFIT1B nearly abrogated 48S complex for-
mation on cap0-b-globin(G) mRNA, whereas hIFIT2,
hIFIT3 and hIFIT5 did not inﬂuence the level of 48S
complex formation (Figure 4A). In addition, consistent
with their binding to cap1- and 50ppp- mRNAs
(Figures 1F, 2D and E), rIFIT1B and hIFIT5 strongly
inhibited 48S complex formation on cap1-b-globin(G)
and 50ppp-b-globin(G) mRNAs, respectively (Figure 4B
and C). Thus, the ability of different IFITs to inhibit
48S complex formation on a speciﬁc mRNA correlated
with their ability to interact with its 50-terminal region
(Figures 1F and 2A–E). Titration experiments showed
that 48S complex formation on cap0-b-globin(G)
mRNA was sensitive even to low concentrations of
hIFIT1, rIFIT1 and rIFIT1B (Figure 4D and E),
whereas inhibition of 48S complex formation on cap1-b-
globin(G) and 50ppp-b-globin(G) mRNAs by rIFIT1B
and hIFIT5 required higher protein concentrations
(Figure 4F and G) (quantitative comparison shown in
Figure 4H). Notably, the IC50 for IFIT1B on cap1-b-
globin(G) was 2-fold lower than would be anticipated
on the basis of the K1/2,app, which suggests that in this
particular case, primer extension might have yielded an
underestimated K1/2,app value due to protein displacement
by RT.
Identiﬁcation of critical residues required for interaction
of hIFIT1 with cap0-mRNAs
The crystal structure of hIFIT5 (Figure 5A) in complex
with short RNAs carrying 50ppp moieties revealed a
narrow, highly charged ssRNA binding cleft (16). A
number of positively charged residues interact with the
phosphate backbone of RNA and are critical for ssRNA
binding by the protein (Figure 5A, right top panel). The
50ppp is recognized by a network of interactions at the rear
of the binding cleft such that there is insufﬁcient space to
accommodate the N7-methylguanosine portion of the cap
structure. However, our structural evaluation indicated
that N7-methylguanosine could be accommodated in the
cleft with minimal disruption to RNA phosphate
backbone and base binding if the trajectory of the ppp
in the hIFIT1 binding pocket differed from that in
hIFIT5 (Figure 5A, right bottom panel). To investigate
whether the 50-terminal region of cap0-mRNA occupies
the same cleft in hIFIT1 as the 50-terminal region of
50ppp-RNA in hIFIT5, we generated a panel of 12
hIFIT1 mutants (Figure 5B; Supplementary Figure S3)
Figure 2. Continued
(D and E) Representative gels of titration of the association of (D) rIFIT1B and (E) hIFIT5 with cap1- and 50ppp- b-globin(G) mRNAs, respectively,
assayed by primer extension. Toe-prints induced by the IFIT/mRNA interaction are indicated. (F and G) Binding of hIFIT1, hIFIT2, hIFIT3,
hIFIT5, rIFIT1 and rIFIT1B (30, 60, 120, 250 nM) to 32P-labeled cap0- (F) and cap1- (G) RNAs comprising 50-terminal 62 nt of b-globin(G) mRNA
(F, upper panel) assayed by EMSA. (H) Binding of eIF4E (2 mM) to 32P-labeled cap0-, cap1- and 50ppp- 62 nt-long RNA (F, upper panel) assayed by
EMSA. ‘U’ and ‘B’ indicate unbound and bound RNAs, respectively (F–H).
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and examined their ability to bind cap0-b-globin(G)
mRNA and inhibit 48S complex formation on it.
One set of mutations consisted of substitutions of
residues (D34, K259 and R262), whose equivalents
interact with 50ppp-RNA in the hIFIT5 crystal structure
and have been found to inﬂuence binding of RNA to
hIFIT5 or hIFIT1. E33 of hIFIT5 interacts with an ion,
likely Mg2+, that bridges the a- and g-phosphates of
50ppp-RNA (16), and substitution by Ala of the equivalent
D34 in hIFIT1 abrogated its ability to bind to cap0-b-
globin(G) mRNA (as evidenced by the disappearance of
the toe-print at the +67 positions; Figure 5C) and to
inhibit 48S complex formation (Figure 5D). This D34A
substitution in hIFIT1 and to a lesser extent the analogous
E33 substitution in hIFIT5 inhibited their binding to
50ppp-RNA (16). In hIFIT5, K257 and R260 make a
salt bridge with the 50-phosphate of the third nucleotide
and are required for binding to 50ppp-RNA (16,18).
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Figure 3. The inﬂuence of N7-methylation on the association of hIFIT1, rIFIT1 and rIFIT1B with cap0 mRNA. (A–C) Binding of (A) hIFIT1, (B)
rIFIT1 and (C) rIFIT1B to N7-methylated and unmethylated cap0-b-globin(G) mRNAs, assayed by primer extension. (D and E) Competition of
hIFIT1 (left panels) and rIFIT1B (right panels) with eIF4E (D) and eIF4F (E) for binding to cap0-b-globin(G) mRNA, assayed by primer extension.
Toe-prints induced by the IFIT/mRNA interaction are indicated (A–E).
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Similarly, K259E and R262E substitutions of equivalent
residues in hIFIT1 abrogated its ability to bind to cap0-b-
globin(G) mRNA and to inhibit 48S complex formation
(Figure 5C and D). The neighboring R263E mutation also
impaired the activity of hIFIT1 (Figure 5C and D). Thus,
the residues that are involved in the interaction of IFIT5
with 50ppp-RNA are also critical for binding of cap0
mRNA by IFIT1.
The second set of mutations targeted residues (F45,
Y50, W147 and Y218), which could participate in forma-
tion of a hypothetical pocket for accommodation of N7-
methylguanosine (Figure 5A, right bottom panel). W147L
and Y218A substitutions completely abrogated the ability
of hIFIT1 to bind to cap0-b-globin(G) mRNA and to
inhibit 48S complex formation (Figure 5C and D).
Interestingly, hIFIT1 mutants containing F45A or Y50A
substitutions at the top of the RNA binding cleft
produced only weak toe-prints at the +67 position
(Figure 5C), but strongly inhibited 48S complex formation
(Figure 5D), suggesting that they can bind cap0 RNA
almost as efﬁciently as the wt protein but are more
readily displaced by RT during toe-printing. The double
mutation F45A/Y50A nearly abrogated the ability of
hIFIT1 to bind to cap0-b-globin(G) mRNA and to
inhibit 48S complex formation (Figure 5C and D).
Although it cannot be strictly excluded that substitution
of these hydrophobic residues could inﬂuence the struc-
ture of the pocket or even the protein, we note that these
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Figure 4. Inhibition of 48S complex formation on cap0-, cap1- and 50ppp- mRNAs by hIFIT1, hIFIT2, hIFIT3, hIFIT5, rIFIT1 and rIFIT1B.
(A–C) Toe-printing analysis of 48S complex formation on (A) cap0-, (B) cap1- and (C) 50ppp- b-globin(G) mRNAs from 40S subunits, eIFs 2, 3, 1,
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formation by rIFIT1B on cap0- and cap1- b-globin(G) mRNAs and by hIFIT5 on 50ppp-b-globin(G) mRNA. The efﬁciency of 48 S complex
formation in the presence of IFITs (panels E–G) was quantiﬁed relative to that in their absence, which was deﬁned as 100%.
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(continued)
mutants all efﬁciently expressed and puriﬁed as soluble
proteins, and behaved identically to the wt IFIT1 during
native gel electrophoresis (Supplementary Figure S4).
Taken together, the results of mutational analysis con-
ﬁrmed that the same RNA binding cleft in hIFIT1 is re-
sponsible for binding both 50ppp- and cap0- RNAs, and
revealed that both hydrophobic and charge–charge inter-
actions within the cleft contribute to optimal cap0-RNA
binding.
The conserved nature of the RNA-binding pockets of
IFIT5 and IFIT1 raises the question of why only IFIT1 is
able to interact with cap0-RNA. One obvious exception to
the conserved character of the RNA binding cleft is the
presence of R38 in hIFIT1 as compared to T37 at an
analogous location in hIFIT5 (Figure 5A, right middle
panel). In the IFIT5/RNA complex, T37 stabilizes K150,
which interacts with the 50ppp at both the b and g pos-
itions: both residues are essential for binding of IFIT5 to
50ppp-RNA (16). An R38A substitution abrogated the
ability of hIFIT1 to bind to cap0-b-globin(G) mRNA
and inhibit 48S complex formation (Figure 5C and D).
The position of R38 might enable it to support an inter-
action between hIFIT1 and cap0 in which the location of
the ppp moiety is distinct from that in the hIFIT5/50ppp-
RNA co-crystal structure. Moreover, the absence in IFIT1
of the stabilizing inﬂuence of a Thr residue at this location
may free K151 (homologous to K150 in hIFIT5) to con-
tribute to interaction with the ppp in the new trajectory.
Finally, substitution of F390 and K417, which are distal
to the RNA binding cleft and located in a region that has
been implicated in IFIT5’s interaction with tRNA (17;
Figure 5A), had a very weak effect on hIFIT1 activity
(Figure 5C and D) indicating that the charged cleft is
the principal determinant of binding of cap0-RNA.
Interestingly, both mutations (but particularly K417A)
increased the relative prominence of the +6nt toe-print,
indicating that these residues could be involved in IFIT1’s
interaction with nucleotides that are more distal from the
50-end. In fact, if the positions of the ﬁrst four nucleotides
of cap0-RNA bound to IFIT1 are similar to those on
IFIT5, then the sixth nucleotide would reach K417.
Interaction of hIFIT1, hIFIT2, hIFIT3, hIFIT5, rIFIT1
and rIFIT1B with tRNAs
The reported ability of IFIT5 to interact with tRNA (17)
prompted us to characterize the tRNA-binding activity of
other IFITs. First, we investigated association of hIFIT1,
hIFIT2, hIFIT3, hIFIT5, rIFIT1 and rIFIT1B (at a con-
centration of 400 nM) with [32P]-labeled Met-tRNAi
Met,
using EMSA (Figure 6A). The most efﬁcient binding
was observed for rIFIT1, rIFIT1B and hIFIT5, whereas
binding of hIFIT1 was somewhat lower. In contrast,
hIFIT2 showed very low afﬁnity to Met-tRNAi
Met, and
no binding was detected in the case of hIFIT3. rIFIT1 and
hIFIT5 bound to Met-tRNAi
Met as monomers, a small
proportion of hIFIT1 formed dimers and higher order
oligomers, whereas almost all rIFIT1B formed very
large, slowly migrating oligomers. Interestingly, inclusion
of eIF2 in a reaction mixture with Met-tRNAi
Met and
rIFIT1B resulted in a speciﬁc supershift (Figure 6B), sug-
gesting the possibility of simultaneous interaction of
rIFIT1B and eIF2 with the same tRNA molecule, or of
direct interaction between eIF2 and rIFIT1B.
To investigate whether association with tRNA inﬂu-
ences binding of hIFIT1, rIFIT1 and rIFIT1B to the
cap-proximal regions of cap0-mRNAs, competition ex-
periments were performed. At a 10-fold excess over
cap0-mRNA, tRNAi
Met reduced association of hIFIT1,
rIFIT1, rIFIT1B with cap0-b-globin(G) mRNA to 38%,
25% and 21%, respectively (Figure 6C). Although the
ability to inhibit IFIT/cap0-mRNA interaction was not
restricted to tRNAi
Met, other tested tRNAs (tRNAHis,
tRNALeu and tRNALys) showed lower activity, and
when included at a 10-fold excess, reduced association of
hIFIT1, rIFIT1, rIFIT1B with cap0-b-globin(G) mRNA
by 40–44% (Figure 6D).
Investigation of the inﬂuence of hIFIT1 and rIFIT1B on
43S preinitiation complex formation
The ability to interfere with the assembly of 43 S
preinitiation complexes has previously been suggested
for hIFIT1 (30,31). We therefore decided to investigate
the ribosomal binding activity of hIFIT1 and its inﬂuence
on 43S complex formation using an in vitro reconstituted
translation system. From among all tested IFITs, rIFIT1B
and hIFIT1 were able to bind stably to 40S subunits and
to remain associated with them during SDG centrifuga-
tion (Figure 7A). rIFIT1B bound more strongly than
hIFIT1, but both were nevertheless present in sub-
stoichiometric amounts relative to 40S subunits, possibly
due to the stringency of centrifugation. Interaction of both
hIFIT1 and rIFIT1B with 40S subunits and Met-
tRNAi
Met (Figure 6) prompted us to compare their inﬂu-
ence on 43S complex formation. 43S complexes were
assembled from 40S subunits, [35S]Met-tRNAi
Met and
eIFs 2, 3, 1 and 1A, and analyzed by SDG centrifugation
(Figure 7B). Neither hIFIT1 nor rIFIT1B affected 43S
complex formation irrespective of whether [35S]Met-
tRNAi
Met (top panel), 40S subunits (middle panel), or
[35S]Met-tRNAi
Met and eIF2 (bottom panel) were
preincubated with an excess of IFITs. Both IFITs also
remained associated with 43S complexes during SDG cen-
trifugation (Figure 7C).
Figure 5. Continued
hIFIT1 RNA binding cleft and the trajectory of the 50-ppp in the hIFIT5 co-crystal structure is shown for comparison. Structure ﬁgures and
alignments were generated using PyMol (Schro¨dinger). (B) Recombinant hIFIT1 mutants resolved by SDS-PAGE. (C) Interaction of hIFIT1 mutants
(100 nM) with cap0-b-globin(G) mRNAs assayed by primer extension. Toe-prints induced by the IFIT1/mRNA interaction were quantiﬁed to
determine the proportion of bound mRNA (%). (D) Inhibition by hIFIT1 mutants (100 nM) of 48S complex formation on cap0-b-globin(G)
mRNA from 40S subunits, eIFs 2, 3, 1, 1A, 4A, 4B and 4F, and Met-tRNAi
Met, assayed by toe-printing. Toe-prints corresponding to 48S complexes
assembled in the presence of wt or mutant hIFIT1 were quantiﬁed relative to those observed in the absence of hIFIT1, which were deﬁned as 100%.
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DISCUSSION
Here we report that IFIT1 and IFIT1B (but not IFIT2,
IFIT3 or IFIT5) bind speciﬁcally and with high afﬁnity to
the cap-proximal regions of cap0-mRNAs (K1/2,app 9 to
23 nM for b-globin cap0-mRNA). Interaction with
mRNA occurs in a region of these proteins that is analo-
gous to the narrow positively charged RNA-binding cleft
in IFIT5 that accommodates 50ppp-RNAs (16,18).
Binding of IFIT1 and IFIT1B to cap0-mRNAs abrogates
48S complex formation in the in vitro reconstituted trans-
lation system.
The afﬁnity of IFIT1 and IFIT1B enables them to out-
compete eIF4E and eIF4F for binding to cap0-mRNA
(Figure 3D and E). The ability of IFITs to outcompete
individual eIF4E is consistent with its modest afﬁnity to
m7GTP, for which Kd values in the majority of reports
range from 140 to 260 nM, depending on the methodology
and conditions used for the analysis (e.g. 48–50). The
exact afﬁnity for the cap of eIF4E as a subunit of eIF4F
has not been determined, but it appears not to contribute
signiﬁcantly to the overall afﬁnity of eIF4F for mRNA,
because the apparent dissociation constants for binding of
eIF4F to capped and uncapped mRNAs differ only
slightly (18±7nM and 23±7nM for b-globin mRNA,
respectively) (51). Although the overall afﬁnity of eIF4F
for mRNA is similar to that of IFIT1 and IFIT1B, IFITs
strongly outcompete eIF4F for binding to cap0 mRNA.
This suggests that the afﬁnity of eIF4E bound to eIF4G
within the eIF4F complex for the cap-terminal region of
RNA is still substantially lower than that of IFIT1 and
IFIT1B.
Interaction of cap-binding proteins with the cap
commonly involves sandwiching of the methylated
guanine base between two aromatic residues (e.g. W56/
W102 in eIF4E, Y20/Y43 in the nuclear cap-binding
protein CBC20, Y22/F180 in the vaccinia virus VP39 20-
O-methyltransferase and F104/H357 in the inﬂuenza virus
polymerase subunit PB2) (52–56). However, sandwiching
between aromatic and aliphatic residues has also been
reported (e.g. W175/L206 in the scavenger decapping
enzyme Dcps) (57). N7-methylation of guanine results in
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delocalization of the positive charge on the base in its
cationic form, which enhances the interactions with the
p-electrons of the stacked aromatic rings (58,59), account-
ing for the speciﬁcity of binding to the N7-methylated cap
over its unmethylated counterpart. In most instances, the
enhancement of binding by N7-methylation is strong,
amounting to 2 to 3 orders of magnitude for eIF4E (60),
eIF4E3 (49) and CBC20 (61). The putative pocket in
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IFIT1 that could accommodate the m7G moiety includes
several aromatic residues, of which W147 and Y218 were
critical for binding of IFIT1 to cap0-mRNA (Figure 5),
and could therefore be directly involved in cap recogni-
tion. However, any speculation concerning potential
stacking interactions involving these residues is premature
because considerable conformational change occurs in
IFIT5 as a consequence of its binding to 50ppp-RNA
(16), and might similarly accompany binding of cap0-
RNA to IFIT1. Although N7-methylation enhanced the
afﬁnity of IFIT1 and IFIT1B for cap0-RNA by only
3.5 - and 10-fold, respectively, these modest increases
are not unprecedented, as a similar 5-fold enhancement
was reported for the inﬂuenza PB2 polymerase subunit
(56). Low dependence on N7-methylation suggests that
interactions other than with m7G contribute signiﬁcantly
to the afﬁnity of IFIT1 and IFIT1B to cap0-RNAs. The
afﬁnity of several cap-binding proteins to capped mRNA
is known to be enhanced by cap-proximal nucleotides.
Thus, binding of CBC20 to the cap is enhanced by the
ﬁrst 2 nt, and inﬂuenza PB2 requires at least 4 nt for efﬁ-
cient interaction and binds even more strongly if 9 nt are
present (62). Based on the arrest of RT at positions
+68 nt from the 50-end on the IFIT1/cap0-RNA and
IFIT1B/cap0-RNA complexes, the interaction of IFIT1
and IFIT1B with mRNA also involves at least 4–5 nt,
which is in turn consistent with the number of nucleotides
that are observed to interact with IFIT5 in the co-crystal
structure (16).
The interaction of IFIT1 with RNA was abrogated by
20-O-methylation: in primer extension inhibition experi-
ments, no binding was observed for human and rabbit
IFIT1 to cap1-mRNA. rIFIT1B, on the other hand,
retained the ability to bind to cap1-RNA, but with an
afﬁnity (K1/2,app 450 nM) that was more than one order
of magnitude lower than for cap0-RNA (K1/2,app 9 nM).
If the paths for the ﬁrst 4 nt of RNA bound to IFIT1 and
IFIT1B are similar to that of 50ppp-RNA bound to IFIT5,
then a clash of the 20-O-methyl group of cap1-RNA with
R187 of IFIT1 (R186 in IFIT5) might be expected. Stable
binding was also observed between IFIT5 and 50ppp-
mRNA, with an afﬁnity (K1/2,app 400 nM) that is com-
parable to that determined previously by EMSA
(Kd=250–500 nM) (16). IFIT1, on the other hand, did
not stably interact with 50ppp-mRNA, even though
moderate-afﬁnity binding of IFIT1 to such RNAs was
detected by surface plasmon resonance (Kd 240 nM)
(10). Although this discrepancy could be explained by
potential displacement of IFIT1 by RT during primer
extension, the fact that in contrast to IFIT5, IFIT1 did
not inhibit 48S complex formation on 50ppp-mRNA
suggests that its afﬁnity to 50ppp-mRNA is lower
than that of IFIT5. Importantly, although detected,
interactions of IFIT1B and IFIT5 with cap1- and 50ppp-
mRNAs were substantially weaker than speciﬁc inter-
actions of IFIT1 and IFIT1B with cap0-mRNAs.
Similarly to IFIT5 (17), IFIT1 and IFIT1B also bound
to initiator tRNA. In IFIT5, the tRNA-binding surface
was assigned to an area in close proximity to the entrance
of the 50ppp-RNA-binding pocket (17; Figure 5A), and
tRNA binding to this site on hIFIT5, or to a homologous
position on hIFIT1, would be expected to occlude the
narrow ssRNA binding cleft. The observed competition
between initiator tRNA and cap0-mRNA for binding to
IFIT1 and IFIT1B is consistent with this model. Although
initiator tRNA was the best competitor, the fact that other
tested elongator tRNAs were also able to interfere with
the binding of IFITs to cap0-mRNA is indicative of the
low speciﬁcity of IFIT/tRNA binding. hIFIT1 and
rIFIT1B were also able to interact with 40S subunits,
which could potentially involve a non-speciﬁc interaction
between exposed elements of 18S rRNA and the tRNA-
binding regions of these IFITs. In any case, this inter-
action is not very strong since both IFITs were bound to
40S subunits in sub-stoichiometric amounts. Importantly,
despite their interactions with initiator tRNA and the 40S
subunit, IFIT1 and IFIT1B did not interfere with the
assembly of 43S preinitiation complexes, as suggested
for human IFIT1 (30,31).
Although the various IFITs could bind tRNA and 40S
subunits, the activity of individual IFITs in inhibiting 48S
complex formation on a speciﬁc mRNA was determined
by their ability to interact speciﬁcally with its 50-terminal
region. The strongest inhibition was mediated by IFIT1
and IFIT1B on cap0-mRNA, followed by IFIT1B-
mediated inhibition on cap1-mRNA, and then by inhib-
ition on 50ppp-mRNA by IFIT5. Other combinations of
IFITs and mRNAs did not exhibit any inhibition. Taking
the level of inhibition into account, suppression of initi-
ation on cap0-mRNAs by IFIT1 and IFIT1B is likely to
be physiologically the most important. The abundance of
IFIT1 and IFIT1B and their ability to competitively
inhibit binding of eIF4F to cap0-mRNAs form the basis
of a mechanism for regulation of translation of any
mRNA that has a 50-terminal cap0. The lack of speciﬁcity
of the IFIT1(IFIT1B)/cap0-mRNA interaction differenti-
ates this mechanism from others that sequester the cap of
speciﬁc mRNAs to prevent their functional interaction
with eIF4F, such as the enhanced binding of the
Drosophila 4E-homologous protein (d4EHP) to the 50-ter-
minal cap of Caudal mRNA by Bicoid (which binds
d4EHP and the 30UTR of Caudal mRNA) (63), and of
eIF4E to the cap of OskarmRNA by Cup (which interacts
with eIF4E and the Oskar 30UTR-binding protein Bruno)
(e.g. 64).
Expression of IFIT1 is strongly up-regulated in response
to viral infection by IFN-dependent and -independent
mechanisms (8,65), and IFIT1-mediated translational
regulation likely primarily targets viral mRNAs.
However, IFIT1 may also have other targets, since it is
constitutively expressed in various cells including
human skin ﬁbroblasts (66) and some sarcoma cell lines
(67), over-expressed in CD34+ cells of patients with
hematopoetic malignancies (68) and inﬂuences the radi-
ation sensitivity of early-stage breast cancer (69).
IFIT1B is thought not to be expressed in an IFN-
dependent manner (11), but as neither the cell types in
which it occurs nor the circumstances that induce its
expression are known, speculation about its physiological
importance in translational control mechanisms is prema-
ture. However, it clearly has the potential to act as a more
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wide-ranging inhibitor of translation than IFIT1, because
of its ability to bind to cap1-mRNAs.
Which mRNAs are potential regulatory targets for the
cap0-binding activity of IFIT1 and IFIT1B? Viruses such
as Sindbis virus do not encode a 20-O-methyltransferase,
and their cap0-mRNAs are therefore strong candidates for
inhibition by IFIT1 and IFIT1B. Consistently, Sindbis
virus replication was impaired by over-expression of
IFIT1 and enhanced by its siRNA-mediated silencing
(21). Moreover, the absence of IFIT1 in Iﬁt/ mice and
murine embryonic ﬁbroblasts and macrophages enhanced
replication of 20-O-methylation-defective mutant forms of
human coronavirus 229E and mouse hepatitis virus
(family Coronaviridae), poxvirus (family Poxviridae),
West Nile virus and Japanese encephalitis virus (family
Flaviviridae), which are normally very sensitive to innate
immune responses (22,35,70–72). For most viruses, the
enzymes that catalyze N7-methylation and 20-O-methyla-
tion of viral mRNA are part of either a multi-domain
protein or a ‘cap assembly line’, and the reactions are
consequently tightly coupled (2). However, in some in-
stances they may be temporally separated, for example if
they are catalyzed by enzymes that function in a deﬁned
order (such as the SARS-coronavirus nsp14 guanine-
N7-methyltransferase and nsp10/nsp16 nucleoside-
20-O-methyltransferase) (73). In such cases, it would
hypothetically be possible for IFIT1 to sequester viral
mRNAs after synthesis of cap0 but before completion of
cap1 formation.
Inhibition of translation of cellular mRNAs by IFIT1
would also require the presence of ‘cap0’ at their
50-termini. Formation of cap0 is a co-transcriptional
process, and mRNAs that lack the N7-methyl moiety
are recognized as being incorrectly capped and are
degraded (74), whereas correctly capped mRNAs are se-
quentially methylated at the 20-hydroxyl position of
the ﬁrst and second transcribed riboses by nuclear
and cytoplasmic cap-speciﬁc 20-O nucleoside RNA
methytransferases, respectively, yielding cap1 and cap2
structures (e.g. 75). If there were a failure of capping to
proceed beyond cap0 formation, the resulting mRNAs
would be susceptible to regulation by IFIT1, and it is con-
ceivable that IFIT1 might function as part of a complex
that detects and degrades incompletely capped mRNAs.
However, cap0-mRNAs appear to be stable, at least in
some circumstances, since stored maternal mRNA in
Xenopus oocytes undergo maturation-dependent 20-O-
methylation, which is thought to contribute to their trans-
lational activation (76–78). Temporal separation of cap
formation and 20-O-methylation could thus occur in a
regulated manner. The 20-O-methylation to form cap1
has only a modest effect on ribosomal recruitment per se
(79), so that its suggested role in translational activation
could potentially reﬂect relief from IFIT-mediated repres-
sion rather than direct enhancement. Another circum-
stance that leads to the accumulation of uncapped
mRNAs involves the regulated decapping and partial
removal of the 50UTR from mRNAs in the cytoplasm.
It has recently been determined that these mRNAs
can undergo cytoplasmic recapping by an as-yet unidenti-
ﬁed enzyme. This process would yield mRNAs lacking
20-O-methylation, which would thus be susceptible to
IFIT1-mediated sequestration (80,81).
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